Patient-tailored Drug-eluting Stent Choice - A Solution for Patients with Diabetes: Proceedings of Two Satellite Symposia Held at EuroPCR in May 2015 in Paris

Katrina Mountfort, Roxana Mehran, Antonio Colombo, Pieter Stella, Rafael Romaguera, Gennaro Sardella

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Although second-generation drug-eluting stents (DES) have improved outcomes in percutaneous coronary interventions (PCIs), important unmet needs remain. Two symposia at EuroPCR 2015 focused on two challenging scenarios. First, patients with diabetes mellitus (DM) have generally inferior outcomes following PCI. The Cre8™ stent (manufactured by CID Spa, member of Alvimedica Group) has shown unique efficacy in subpopulations of patients with DM during clinical trials. A live case in a patient with diabetes illustrated the challenges of complex multivessel disease. Second, optimising stent selection towards devices that have demonstrated complete and early endothelialisation offers the potential to reduce the duration of dual antiplatelet therapy. The Cre8™ DES features a polymer-free platform and has been associated with low rates of in-stent thrombosis.

Original languageEnglish
Pages (from-to)158-161
Number of pages4
JournalInterventional Cardiology Review
Volume10
Issue number3
DOIs
Publication statusPublished - Sept 2015

Keywords

  • Journal Article

Fingerprint

Dive into the research topics of 'Patient-tailored Drug-eluting Stent Choice - A Solution for Patients with Diabetes: Proceedings of Two Satellite Symposia Held at EuroPCR in May 2015 in Paris'. Together they form a unique fingerprint.

Cite this